Combining insulin and amylin analogues to improve diabetes treatment
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes
This study is looking to create a new treatment for people with type 1 diabetes that combines different hormones to help manage blood sugar levels after meals, making it easier and more convenient for you to keep your diabetes under control.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11137486 on NIH RePORTER |
What this research studies
This research aims to create a new treatment for diabetes by combining insulin analogues with amylin analogues and incretin hormones. The approach focuses on addressing the challenges faced by individuals with type 1 diabetes, particularly in managing blood glucose levels after meals. By developing a co-formulation that mimics the natural hormonal balance, the research seeks to enhance glycemic control and reduce the need for multiple daily injections. Patients may benefit from a more effective and convenient treatment option that better regulates their blood sugar levels.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type 1 diabetes who struggle with blood glucose management.
Not a fit: Patients with type 2 diabetes or those who do not have diabetes may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective treatment for diabetes that improves blood sugar control and reduces the burden of daily insulin injections.
How similar studies have performed: Previous research has shown promise in combining insulin with other hormones for diabetes treatment, indicating potential success for this novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Appel, Eric Andrew — Stanford University
- Study coordinator: Appel, Eric Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.